Friday 6 November 2026 Export ABCL’s income statement to Excel — free account

AbCellera Biologics Inc.

AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.

Revenue: −76.3%
EPS: −50.0%
Free cash flow: +152.0%

Quarter to June 2026, against a year earlier

Insider buying

11.89 0.76 +6.83%

Follow ABCL

Alert me

Market cap: $3.6B
P/E: 0.0×
Fwd P/E: −18.4×
Dividend yield: —
F-score: 5/9
Altman Z: 1.66
Beneish M: −1.06
Dividend safety: n/a

Overview

AbCellera Biologics Inc. (ABCL) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, AbCellera Biologics Inc. (ABCL) trades at a P/S ratio of 54.9×. Over the past ten years it has ranged from 0.0× (December 2020) to 68.4× (September 2026); the current reading is higher than 98% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ABCL/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="AbCellera Biologics Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ABCL/metrics/ps-ratio">AbCellera Biologics Inc. (ABCL) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	13.6×	(54.54%)
FY2024	29.9×	(31.36%)
FY2023	43.6×	681.91%
FY2022	5.6×	(46.98%)
FY2021	10.5×	(61.75%)
FY2020	27.5×	—
FY2019	0.0×	—
FY2018	0.0×	—

Period	P/S ratio	Change
Jun 2026	36.2×	171.44%
Mar 2026	13.4×	(1.79%)
Dec 2025	13.6×	(68.05%)
Sep 2025	42.6×	36.65%
22 more quarters	Free account

Against its own ten years

Low 0.0× High 68.4×

Ten-year median 20.0×

Current reading's percentile 97

Company	P/S ratio
PBLS Parabilis Medicines, Inc. compare	n/m
EWTX Edgewise Therapeutics, Inc. compare	n/m
ACAD ACADIA Pharmaceuticals Inc. compare	3.1×
ARQT Arcutis Biotherapeutics, Inc. compare	7.0×
IOVA Iovance Biotherapeutics, Inc. compare	9.3×
TNGX Tango Therapeutics, Inc. compare	51.0×
ABCL AbCellera Biologics Inc.	51.9×
XENE Xenon Pharmaceuticals Inc. compare	223×
RLAY Relay Therapeutics, Inc. compare	313×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

AbCellera Biologics Inc. (ABCL) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ABCL

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ABCL

Stockrow Weekly